10.13.14
Capsugel announced the broad commercial availability of its proprietary lipid multi-particulate (LMP) technology. Capsugel’s LMP technology is an innovative drug-delivery platform with multiple applications—including bioavailability enhancement, taste-masking and modified release—for both pharmaceutical and health and nutrition (H&N) products. The company’s LMP technology is based on its melt-spray congeal (MSC) processing and combines the benefits of lipid-based formulations (LBF) with the functionality of a multi-particulate dosage form in one unique offering.
"With our LMP technology, Capsugel is again employing its advanced science and engineering to provide clients with innovative options to achieve their target product profiles and commercial objectives,” said Keith Hutchison, PhD, senior vice president, Research & Development, Capsugel. “LMP technology already has a commercialized pharmaceutical product, and we have developed several product applications in the H&N marketplace. Given its performance and flexibility, we expect LMPs to become the right solution to address many client project challenges.”
The expansion of Capsugel’s LMP technology enhances the company’s ability to bring value to healthcare customers around the world by helping them design, develop and manufacture new compounds—and improve existing ones. LMP technology complements Capsugel’s array of bioavailability enhancement technologies, including LBF options in either liquid-filled hard capsules or soft gels for oral delivery. It also adds to the company’s breadth and depth of multi-particulate options offered to clients, which includes fluid-bed-layered, extrusion and mini-tablet approaches. Several client projects are currently evaluating LMP as a formulation option.
“Bringing LMP technology to market has required the successful integration of our capabilities in process development, formulation and specialized production equipment,” added Amit Patel, president, Dosage Form Solutions, Capsugel. “Our premier range of technologies and specialized manufacturing allows clients to have one partner throughout the product development cycle—from design to commercial manufacture of finished dosage forms—offering accelerated speed to market, while reducing overall costs and risks to their program.”
MSC processing for LMP production is currently available at Capsugel’s manufacturing site in Bend, OR, and a commercial-scale facility with MSC processing and capsule-filling capability was recently installed at its location in Greenwood, SC. The company is also continuing to innovate and evolve its global manufacturing processes and capabilities for LMP to extend the reach and applicability for its global customer base. For more information: www.capsugel.com
"With our LMP technology, Capsugel is again employing its advanced science and engineering to provide clients with innovative options to achieve their target product profiles and commercial objectives,” said Keith Hutchison, PhD, senior vice president, Research & Development, Capsugel. “LMP technology already has a commercialized pharmaceutical product, and we have developed several product applications in the H&N marketplace. Given its performance and flexibility, we expect LMPs to become the right solution to address many client project challenges.”
The expansion of Capsugel’s LMP technology enhances the company’s ability to bring value to healthcare customers around the world by helping them design, develop and manufacture new compounds—and improve existing ones. LMP technology complements Capsugel’s array of bioavailability enhancement technologies, including LBF options in either liquid-filled hard capsules or soft gels for oral delivery. It also adds to the company’s breadth and depth of multi-particulate options offered to clients, which includes fluid-bed-layered, extrusion and mini-tablet approaches. Several client projects are currently evaluating LMP as a formulation option.
“Bringing LMP technology to market has required the successful integration of our capabilities in process development, formulation and specialized production equipment,” added Amit Patel, president, Dosage Form Solutions, Capsugel. “Our premier range of technologies and specialized manufacturing allows clients to have one partner throughout the product development cycle—from design to commercial manufacture of finished dosage forms—offering accelerated speed to market, while reducing overall costs and risks to their program.”
MSC processing for LMP production is currently available at Capsugel’s manufacturing site in Bend, OR, and a commercial-scale facility with MSC processing and capsule-filling capability was recently installed at its location in Greenwood, SC. The company is also continuing to innovate and evolve its global manufacturing processes and capabilities for LMP to extend the reach and applicability for its global customer base. For more information: www.capsugel.com
